Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Denmark
100%
Patient Benefit
100%
Cost Savings
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Patient Costs
100%
Chronic Kidney Disease Management
100%
Chronic Kidney Disease
36%
Kidney Failure
27%
Kidney Disease Progression
18%
Kidney Disease
18%
Chronic Kidney Disease Stage
18%
Net Monetary Benefit
18%
Disease Progression Modeling
18%
Clinical Outcomes
9%
Cardiovascular Disease
9%
Treatment Effect
9%
Randomized Controlled Trial
9%
Health Systems
9%
Mortality Rate
9%
All-cause Mortality
9%
Global Burden
9%
Potential Gains
9%
Kidney
9%
Patient Data
9%
Health Outcomes
9%
Patient Care
9%
Real Patients
9%
10-year Risk
9%
Serious Complications
9%
Patient Survival
9%
Aging Population
9%
Uptake Rate
9%
Economic Outcomes
9%
Quality-adjusted Life Years
9%
Healthcare Expenditure
9%
Net Benefit
9%
Analytical Approach
9%
Model Validation
9%
Chronic Disease Prevalence
9%
Decision-analytic Model
9%
10-year Mortality
9%
Model Potential
9%
Microsimulation Model
9%
Plain Language Summary
9%
Healthcare Impact
9%
Kidney Disease: Improving Global Outcomes (KDIGO)
9%
Healthcare Providers
9%
Urinary Albumin-to-creatinine Ratio
9%
State of Health
9%
Expanded Access
9%
Results-based
9%
Markov State
9%
Dynamic Decision
9%
Long Delay
9%
Medicine and Dentistry
Disease Management
100%
Health Care Cost
100%
Chronic Kidney Disease
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Health Care
27%
Nephropathy
27%
Renal Failure
27%
Prevalence
18%
Mortality Rate
9%
Randomized Controlled Trial
9%
Cardiovascular Disease
9%
Health Status
9%
All Cause Mortality
9%
Patient-Data
9%
Treatment Effect
9%
Urinary System
9%
Creatinine
9%
Chronic Disease
9%
Health Outcomes
9%
Uptake Rates
9%
Quality Adjusted Life Year
9%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
9%
Albumin
9%
Health Care Personnel
9%
Plain Language
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Kidney Disease
27%
Kidney Failure
27%
Prevalence
18%
Randomized Controlled Trial
9%
Creatinine
9%
Mortality Rate
9%
All Cause Mortality
9%
Health Status
9%
Chronic Disease
9%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
9%
Albumin
9%
Cardiovascular Disease
9%